← Eichor
Condition: Ovarian Small Cell Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Ovarian Small Cell Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
Phase 1 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT04778839Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients
NA · 1 location(s) · Royal Marsden NHS Foundation Trust · NCT07673861Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Tor
Phase 1 · 3 location(s) · Zumutor Biologics Inc. · NCT06451497A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers
Phase 1 · 7 location(s) · Light Chain Bioscience - Novimmune SA · NCT05403554At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 · 2 location(s) · Mayo Clinic · NCT05969860A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin)
Phase 1/Phase 2 · 58 location(s) · Eisai Inc. · NCT04300556Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanc
Phase 1 · 12 location(s) · Whitehawk Therapeutics, Inc. · NCT07444814The EASE Study: Randomized Trial of a Novel Approach to Addressing Fear of Progression in Advanced Cancer
NA · 2 location(s) · University of Colorado, Boulder · NCT07636200Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT03412877A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Phase 1/Phase 2 · 4 location(s) · Cancer Research UK · NCT06380816Assessment of Compliance With Monitoring Conducted by a Physician in Person or by a Nurse in Remote Monitoring
Phase 2 · 3 location(s) · Centre Oscar Lambret · NCT05500391A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
Phase 1/Phase 2 · 14 location(s) · Volastra Therapeutics, Inc. · NCT05902988A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patien
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07610798Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
Phase 1 · 17 location(s) · NextCure, Inc. · NCT06792552DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cance
Phase 2/Phase 3 · 16 location(s) · Cancer Research UK · NCT05768178A Study of NX-1607 in Adults With Advanced Malignancies
Phase 1 · 17 location(s) · Nurix Therapeutics, Inc. · NCT05107674A Study of DC05F01 in Chinese Patients with Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors
Phase 1/Phase 2 · 2 location(s) · Heronova Pharmaceuticals · NCT06873555A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks
Phase N/A · 1 location(s) · Fondazione del Piemonte per l'Oncologia · NCT07469709Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
Phase 1 · 3 location(s) · BioEclipse Therapeutics · NCT04282044DESTINY-PANTUMOUR04
Phase N/A · 18 location(s) · AstraZeneca · NCT0712400018F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 · 1 location(s) · National Cancer Institute (NCI) · NCT06503146Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 · 5 location(s) · Conjupro Biotherapeutics, Inc. · NCT07424547The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel
Phase N/A · 4 location(s) · Javier Toledo · NCT06717295A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Phase 1/Phase 2 · 67 location(s) · AstraZeneca · NCT05123482Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing So
Phase 1 · 7 location(s) · Myeloid Therapeutics · NCT07334119
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.